Source link : https://www.newshealth.biz/health-news/radium-223-plus-enzalutamide-ups-survival-in-prostate-cancer/
BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and bone metastases significantly improves survival outcomes, according to the first results from the PEACE III trial. The research, presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2024, demonstrated a […]
Author : News Health
Publish date : 2024-09-17 06:26:33
Copyright for syndicated content belongs to the linked Source.
inHealth